Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

PRESS RELEASE

SNBL

Sep 16, 2026

SNBL's Greenhouse Gas Emissions Reduction Targets Validated by the Science Based Targets initiative (SBTi)

TOKYO and KAGOSHIMA, Japan, September 16, 2026 – Shin Nippon Biomedical Laboratories, Ltd. (TSE Prime: 2395, Representative Director, President: Hideyuki Hirama, "SNBL") is pleased to announce that its greenhouse gas (GHG) emissions reduction targets have been validated by the Science Based Targets initiative (SBTi) on September 15, 2026. The validation confirms that SNBL's targets are science-based and aligned with the 1.5°C goal of the Paris Agreement.

The SBTi is a global organization that enables companies and financial institutions to take science-based climate action. It assesses and validates, on a scientific basis, whether the GHG emissions reduction targets set by companies are consistent with the goal of the Paris Agreement to limit the rise in global average temperature to 1.5°C above pre-industrial levels.

In recent years, extreme weather events linked to global warming -- including severe heat and heavy rainfall -- have intensified around the world, making the response to climate change a matter close to all of us. The SBTi validation demonstrates that SNBL, having set science-based targets, is actively working together with its customers and business partners to help address climate change.

Based on its corporate philosophy of “Committed to the Environment, Life and People” and its slogan “I'm happy, you're happy, and everyone is happy”, SNBL strongly believes that advancing sustainability is essential to its sustainable growth, and will continue to create economic and social value in an integrated manner.

SCIENCE BASED TARGETS
DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

The official validated target language:
Near-Term
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. commits to reduce absolute scope 1 and 2 GHG emissions 52.62% by FY2034 from a FY2024 base year. SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. also commits that 78.3% of its suppliers and customers by emissions covering purchased goods and services, capital goods, upstream transportation and distribution, and investments, will have science-based targets by FY2031.

Inquiries:
Shin Nippon Biomedical Laboratories, Ltd.
IR & Corporate Communications
Email: ir@snbl.com
Website: https://en.snbl.com/

#####

Forward-Looking Statements

This communication contains forward-looking statements, including statements regarding the impact of general economic, industry, market, or political conditions. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe," and other similar expressions (or the negative of such terms) are intended to identify forward-looking statements. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results and the timing of events may differ materially from the results and/or timing discussed in the forward-looking statements, and readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date of this communication, and SNBL does not undertake any obligation to update any forward-looking statement except as required by law.